Clinical Trials for Stephen Strickland
10 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCHEM1289 01/04/2013 | Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML |
| Therapeutic | VICCHEM1151 08/17/2012 | Randomized Phase II Trial of Timed Sequential Therapy (TST) with Alvocidib (Flavopiridol), ara-C and mitoxantrone (FLAM) vs. "7+3" for Adults age 70 and Under with Newly Diagnosed Acute Myelogenous Leukemia (AML) |
| Therapeutic | ECOGHEME2906 01/20/2012 | Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years) |
| Therapeutic | VICCHEM1096 10/24/2011 | A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia |
| Therapeutic | VICCHEM1095 08/03/2011 | A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR) |
| Therapeutic | VICCPHI1050 01/17/2011 | A Phase Ib, Dose-Finding Study of Oral Panobinostat (LBH589) in Combination with Idarubicin and Cytarabine Induction and High-Dose Cytarabine-Based Consolidation Therapy in Adult Patients Less and or Equal to 65 Years Old with Acute Myeloid Leukemia (AML) |
| Therapeutic | VICCPHI1040 12/21/2010 | A Phase I Study to Evaluate the Safety and Clinical Activity of WT1-A10+AS01B Antigen Specific Cancer Immunotherapeutic in Adult Patients with WT1-Positive Acute Myeloid Leukemia in Partial Remission with Incomplete Blood Count Recovery Post-Induction Therapy |
| Ancillary | VICCHEM1073 08/19/2011 | The Role of the Native Immune System in Determining Outcome Following AML Induction Therapy |
| Ancillary | ECOGHEME3903 06/07/2005 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders |
| Supportive-Therapeutic | PRECOGHEM0901 12/04/2012 | Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
